{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:19:22Z","timestamp":1719926362576},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000849","name":"NC3Rs","doi-asserted-by":"publisher","award":["G0900775"],"award-info":[{"award-number":["G0900775"]}],"id":[{"id":"10.13039\/501100000849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.yebeh.2015.06.009","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T02:25:37Z","timestamp":1437186337000},"page":"290-293","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["New experimental therapies for status epilepticus in preclinical development"],"prefix":"10.1016","volume":"49","author":[{"given":"Matthew C.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin S.B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2015.06.009_bb0005","first-page":"435","article-title":"Pharmacodynamic properties of N-dipropylacetic acid","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0010","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","article-title":"Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam \u2014 pilot study","volume":"114","author":"Mundlamuri","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0015","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1528-1167.2011.03056.x","article-title":"Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam","volume":"52","author":"Alvarez","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0020","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.yebeh.2015.02.040","article-title":"Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide \u2014 amide derivatives of valproic acid","volume":"46","author":"Mawasi","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0025","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1185\/03007995.2012.694362","article-title":"Valproate-induced hyperammonemic encephalopathy: a brief review","volume":"28","author":"Lewis","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0030","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/brain\/awn007","article-title":"POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection","volume":"131","author":"Engelsen","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0035","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.85.2213.525","article-title":"Experimental determination of the anticonvulsant properties of some phenyl derivatives","volume":"85","author":"Putnam","year":"1937","journal-title":"Science"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0040","first-page":"29","article-title":"The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy","volume":"76","author":"White","year":"1998","journal-title":"Adv Neurol"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0045","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.seizure.2014.09.018","article-title":"Epilepsy research methods update: understanding the causes of epileptic seizures and identifying new treatments using non-mammalian model organisms","volume":"24C","author":"Cunliffe","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0050","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature03481","article-title":"The genome of the social amoeba Dictyostelium discoideum","volume":"435","author":"Eichinger","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0055","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.molmed.2006.07.003","article-title":"Towards a molecular understanding of human diseases using Dictyostelium discoideum","volume":"12","author":"Williams","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0060","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1128\/EC.00104-06","article-title":"Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid","volume":"6","author":"Xu","year":"2007","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0065","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-60761-198-1_19","article-title":"Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells","volume":"571","author":"Pawolleck","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0070","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1242\/dmm.008029","article-title":"The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium","volume":"5","author":"Chang","year":"2012","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0085","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0920-1211(98)00030-8","article-title":"Effects of new valproate derivatives on epileptiform discharges induced by pentylenetetrazole or low Mg2+ in rat entorhinal cortex\u2013hippocampus slices","volume":"32","author":"Armand","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0080","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1042\/BST20130183","article-title":"The search for better epilepsy treatments: from slime mould to coconuts","volume":"41","author":"Walker","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0075","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.nbd.2013.10.017","article-title":"Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid","volume":"62","author":"Chang","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0090","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuropharm.2012.11.004","article-title":"Seizure control by ketogenic diet-associated medium chain fatty acids","volume":"69","author":"Chang","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0095","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1124\/jpet.114.218768","article-title":"Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency","volume":"352","author":"Chang","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0100","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.eplepsyres.2011.05.021","article-title":"The ketogenic diet: what has science taught us?","volume":"100","author":"Rho","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/clinchem\/28.4.642","article-title":"Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet","volume":"28","author":"Haidukewych","year":"1982","journal-title":"Clin Chem"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0110","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0000000000000151","article-title":"Ketogenic diet for adults in super-refractory status epilepticus","volume":"82","author":"Thakur","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0115","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2013.07.020","article-title":"The ketogenic diet for the treatment of pediatric status epilepticus","volume":"50","author":"O'Connor","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2015.06.009_bb0120","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/1531-8249(20010201)49:2<260::AID-ANA49>3.0.CO;2-Y","article-title":"Propofol in subanesthetic doses terminates status epilepticus in a rodent model","volume":"49","author":"Holtkamp","year":"2001","journal-title":"Ann Neurol"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015003406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015003406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T05:48:21Z","timestamp":1599284901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505015003406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":24,"alternative-id":["S1525505015003406"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.06.009","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New experimental therapies for status epilepticus in preclinical development","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}